Corbus Pharmaceuticals Holdings (CRBP) Accumulated Expenses (2013 - 2025)

Corbus Pharmaceuticals Holdings' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $2.9 million for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 25.62% year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $2.9 million (up 25.62% YoY), while the FY2025 annual figure was $2.9 million, up 25.62% from the prior year.
• Accumulated Expenses was $2.9 million for Q4 2025 at Corbus Pharmaceuticals Holdings, down from $12.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $15.1 million in Q2 2021 to a low of $1.4 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $5.0 million across 5 years, with a median of $3.1 million in 2021.
• The sharpest annual moves came in 2021 and 2025: Accumulated Expenses sank 88.33% in 2021, then surged 589.96% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $10.1 million in 2021, then plunged by 77.96% to $2.2 million in 2022, then soared by 395.74% to $11.0 million in 2023, then slumped by 79.37% to $2.3 million in 2024, then advanced by 25.62% to $2.9 million in 2025.
• The last three Accumulated Expenses figures came in at $2.9 million (Q4 2025), $12.6 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.